PMID- 24748641
OWN - NLM
STAT- MEDLINE
DCOM- 20141021
LR  - 20151119
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
VI  - 99
IP  - 9
DP  - 2014 Sep
TI  - Safety of medicines used for ADHD in children: a review of published prospective 
      clinical trials.
PG  - 866-72
LID - 10.1136/archdischild-2013-304170 [doi]
AB  - OBJECTIVE: To assess the long-term safety of drugs for attention deficit 
      hyperactivity disorder (ADHD). METHODS: A bibliographic search was performed in 
      the MEDLINE, EMBASE and PsycINFO databases for prospective studies evaluating the 
      incidence of adverse events (AEs) in children and adolescents treated for ADHD. 
      RESULTS: A total of six prospective studies that monitored drug safety during 
      therapy for at least 12 weeks were retrieved. The drugs studied were atomoxetine 
      (two studies, 802 patients), osmotic-controlled released oral methylphenidate 
      formulation (two studies, 512 patients), extended release formulation of mixed 
      amphetamine salts (one study, 568 patients) and transdermal methylphenidate (one 
      study, 326 patients). Heterogeneity was found in the duration of follow-up 
      (ranging between 1 and 4 years) and in the way data were reported. The rate of 
      treatment-related AEs ranged from 58% to 78%, and the rate of discontinuation due 
      to AEs ranged from 8% to 25% of the children. Decreased appetite, insomnia, 
      headache and abdominal pain were the most common AEs observed. Most AEs and cases 
      of discontinuation occurred during the first few months of treatment. 
      CONCLUSIONS: Few studies evaluated the long-term safety of drugs for ADHD. 
      Heterogeneity in follow-up duration and in data reporting made comparing 
      different studies and drugs difficult. A systematic monitoring of long-term 
      safety is needed.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Clavenna, Antonio
AU  - Clavenna A
AD  - Laboratory for Mother and Child Health, Department of Public Health, 
      IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
FAU - Bonati, Maurizio
AU  - Bonati M
AD  - Laboratory for Mother and Child Health, Department of Public Health, 
      IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140419
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 0 (Amphetamines)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Propylamines)
RN  - 207ZZ9QZ49 (Methylphenidate)
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
SB  - IM
MH  - Adolescent
MH  - Amphetamines/adverse effects/therapeutic use
MH  - Atomoxetine Hydrochloride
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Central Nervous System Stimulants/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Child
MH  - Humans
MH  - Methylphenidate/adverse effects/therapeutic use
MH  - Propylamines/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Child Psychiatry
OT  - Pharmacology
EDAT- 2014/04/22 06:00
MHDA- 2014/10/22 06:00
CRDT- 2014/04/22 06:00
PHST- 2014/04/22 06:00 [entrez]
PHST- 2014/04/22 06:00 [pubmed]
PHST- 2014/10/22 06:00 [medline]
AID - archdischild-2013-304170 [pii]
AID - 10.1136/archdischild-2013-304170 [doi]
PST - ppublish
SO  - Arch Dis Child. 2014 Sep;99(9):866-72. doi: 10.1136/archdischild-2013-304170. 
      Epub 2014 Apr 19.